secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2025-03-04T23:59:59+00:00
Accession:  0001104659-25-020296
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents postpones Q4/FY2024 earnings to March 25 after controller's death; reaffirms prelim revenue
--------------------------------------------------------------------------------

- Q4 product revenue expected $9.0-9.2M (22-25% YoY growth); full-year $35.4-35.6M (~14% growth).
- Q4 product gross margin ~70%, vs 61% prior quarter and 72% Q4 2023.
- Pro-forma cash balance Dec 31, 2024 ~$17.0M (incl. $7.3M net from rights offering/warrants); Q4 cash burn ~$2.5M.
- DrugSorb-ATR marketing applications under substantive review with FDA and Health Canada; decisions expected in 2025.
- Delay due to unexpected passing of VP and Corporate Controller James E. Cason, Jr.; earnings call rescheduled to March 25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925020296/0001104659-25-020296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465925020296/tm258215d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-020296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer